The purpose of this phase I study in healthy participants will be to evaluate the safety and tolerability of LY2886721 single and multiple doses, how the body handles the drug and the drug's effect on the body.

Single oral dose and/or once daily oral dosing for 14 consecutive days

Drug: Placebo

Administered orally.

Experimental: 35 mg LY2886721

Once daily oral dosing for 14 consecutive days

Drug: LY2886721

Administered orally.

Experimental: 70 mg LY2886721

Single oral dose followed by once daily oral dosing for 14 consecutive days

Drug: LY2886721

Administered orally.

Experimental: 140 mg LY2886721

Single oral dose

Drug: LY2886721

Administered orally.

Eligibility

Ages Eligible for Study:

20 Years and older

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

Yes

Criteria

Inclusion Criteria:

Healthy men and non-childbearing potential women

Body mass index between 18.0-32.0 kg/m^2

Are reliable and willing to make yourself available for the duration of the study and are willing to follow study procedures and research unit policies

Exclusion Criteria:

Taking over-the-counter or prescription medication with the exception of vitamins or minerals

Smoke more than 10 cigarettes per day

Drink more than 5 cups of caffeine containing beverages (e.g., coffee, tea) per day

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01534273